The Journal of Immunology, Vol 159, Issue 6 2658-2667, Copyright © 1997 by American Association of Immunologists

ARTICLES

Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels

Y Kalechman, U Gafter, JP Da, M Albeck, D Alarcon-Segovia and B Sredni
Cancer, AIDS, and Immunology Research Institute, Department of Life Sciences, Bar Ilan University, Ramat Gan, Israel.

It has recently been found that in systemic lupus erythematosus (SLE), a multisystem inflammatory disorder characterized by autoantibody production and decreased cellular immune response, increased spontaneous production of IL-10 occurs. The immunomodulator AS101 (ammonium trichloro(dioxoethylene-0,0')tellurate) was previously shown to significantly decrease IL-10 levels in cancer patients and in murine models. This study shows that AS101 inhibits the development of SLE- related autoimmune pathological manifestations. AS101 decreased the spontaneous IL-10 production by mononuclear cells from SLE patients in vitro. In vivo, systemic injection of AS101 to SCID mice transplanted with mononuclear cells from SLE patients significantly decreased serum human IL-10 levels. There was also a decrease in all serum human Ig isotypes, in anti-dsDNA, and in anti-Sm Igs. In the New Zealand Black/New Zealand White/F1 model, AS101 significantly increased serum TNF-alpha and IFN-gamma while decreasing IL-10 levels; these changes were accompanied by a rapid decrease in anti-dsDNA and anti-ssDNA Igs. More importantly, continuous treatment of New Zealand Black/New Zealand White/F1 mice with AS101 for 6 mo led to the development of proteinuria in 30% of the treated mice compared with 100% in PBS-treated mice (p < 0.001). AS101 treatment reduced the level of immmune complex deposition in the glomeruli, prevented glomerular hypercellularity and mesangial expansion and led to a much smaller mean glomerular volume in treated mice (185 +/- 6 vs 428 +/- 47.103 microm3; p < 0.01). We suggest that treatment with a nontoxic immunomodulator such as AS101, previously used in phase II trials on cancer patients, may be an effective therapeutic approach for controlling SLE.

This article has been cited by other articles:

				B. Sredni, R. Geffen-Aricha, W. Duan, M. Albeck, F. Shalit, H. M. Lander, N. Kinor, O. Sagi, A. Albeck, S. Yosef, et al. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models FASEB J, June 1, 2007; 21(8): 1870 - 1883. [Abstract] [Full Text] [PDF]

				I. Sinuani, Z. Averbukh, I. Gitelman, M. J. Rapoport, J. Sandbank, M. Albeck, B. Sredni, and J. Weissgarten Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: effect of the immunomodulator AS101 on this process Am J Physiol Renal Physiol, August 1, 2006; 291(2): F384 - F394. [Abstract] [Full Text] [PDF]

				M Aringer and J S Smolen Cytokine expression in lupus kidneys Lupus, January 1, 2005; 14(1): 13 - 18. [Abstract] [PDF]

				H. Schotte, M. Gaubitz, P. Willeke, N. Tidow, G. Assmann, W. Domschke, and B. Schluter Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response Rheumatology, November 1, 2004; 43(11): 1357 - 1363. [Abstract] [Full Text] [PDF]

				Y. Kalechman, U. Gafter, T. Weinstein, A. Chagnac, I. Freidkin, A. Tobar, M. Albeck, and B. Sredni Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis: ASSOCIATION WITH DEPHOSPHORYLATION OF STAT3 J. Biol. Chem., June 4, 2004; 279(23): 24724 - 24732. [Abstract] [Full Text] [PDF]

				I Sekigawa, T Naito, K Hira, K Mitsuishi, H Ogasawara, H Hashimoto, and H Ogawa Possible mechanisms of gender bias in SLE: a new hypothesis involving a comparison of SLE with atopy Lupus, April 1, 2004; 13(4): 217 - 222. [Abstract] [PDF]

				B. Sredni, M. Weil, G. Khomenok, I. Lebenthal, S. Teitz, Y. Mardor, Z. Ram, A. Orenstein, A. Kershenovich, S. Michowiz, et al. Ammonium Trichloro(dioxoethylene-o,o')tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop Cancer Res., March 1, 2004; 64(5): 1843 - 1852. [Abstract] [Full Text] [PDF]

				Y. Kalechman, B. Sredni, T. Weinstein, I. Freidkin, A. Tobar, M. Albeck, and U. Gafter Production of the Novel Mesangial Autocrine Growth Factors GDNF and IL-10 Is Regulated by the Immunomodulator AS101 J. Am. Soc. Nephrol., March 1, 2003; 14(3): 620 - 630. [Abstract] [Full Text] [PDF]

				Y. Kalechman, U. Gafter, R. Gal, G. Rushkin, D. Yan, M. Albeck, and B. Sredni Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice from Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention J. Immunol., July 1, 2002; 169(1): 384 - 392. [Abstract] [Full Text] [PDF]

				S. Di Marco, Z. Hel, C. Lachance, H. Furneaux, and D. Radzioch Polymorphism in the 3'-untranslated region of TNF{{alpha}} mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNF{{alpha}} mRNA Nucleic Acids Res., February 15, 2001; 29(4): 863 - 871. [Abstract] [Full Text] [PDF]

				B. O. Lim, C. A. Jolly, K. Zaman, and G. Fernandes Dietary (n-6) and (n-3) Fatty Acids and Energy Restriction Modulate Mesenteric Lymph Node Lymphocyte Function in Autoimmune-Prone (NZB NZW)F1 Mice J. Nutr., July 1, 2000; 130(7): 1657 - 1664. [Abstract] [Full Text]

				C. Gabay, B. Porter, D. Guenette, B. Billir, and W. P. Arend Interleukin-4 (IL-4) and IL-13 Enhance the Effect of IL-1beta on Production of IL-1 Receptor Antagonist by Human Primary Hepatocytes and Hepatoma HepG2 Cells: Differential Effect on C-Reactive Protein Production Blood, February 15, 1999; 93(4): 1299 - 1307. [Abstract] [Full Text] [PDF]

				G G Illei and J H Klippel Novel approaches in the treatment of lupus nephritis Lupus, November 1, 1998; 7(9): 644 - 648. [Abstract] [PDF]